Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The ADAM metallopeptidase domain 29 pseudogene is a sequence in the human genome that resembles the *ADAM29* gene but is considered non-functional and does not encode a protein product. Pseudogenes like this one arise through errors in gene duplication or retrotransposition and typically have no known biological function, do not participate in cellular processes, and are not drug targets or biomarkers. The protein-coding gene *ADAM29* (not the pseudogene) belongs to the ADAM (a disintegrin and metalloprotease) family and has been implicated in cell-cell and cell-matrix interactions, but the pseudogene does not share these properties[1][4].\n\nThe *ADAM29* protein-coding gene (not the pseudogene) is sometimes mistakenly conflated with the pseudogene due to similar naming. The "ADAM metallopeptidase domain 29" gene is a member of a protein family involved in processes like fertilization and neurogenesis and is associated with certain diseases such as melanoma[1][3].\nThe pseudogene (ENSG00000249411) itself does **not code for a receptor, enzyme, transporter, or other druggable target** and has no established biological or therapeutic role.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ADAM metallopeptidase domain 29 pseudogene.